Expertise in
1
conditions

Martin Hoffmann

Ludwigshafen Am Rhein, RP, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Ludwigshafen Am Rhein, RP, DE 

Overview

Martin Hoffmann practices practicing medicine in Ludwigshafen Am Rhein, Germany.

Mr. Hoffmann is highly rated in 1 condition, according to our data. His clinical expertise encompasses Multiple Myeloma, Light Chain Deposition Disease (LCDD), Mantle Cell Lymphoma (MCL), Primary Amyloidosis, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Ludwigshafen Am Rhein, RP, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
View 1 Less Clinical Trial

15 Total Publications

Prospective systematic classification of causes of death in the course of multiple myeloma.
Prospective systematic classification of causes of death in the course of multiple myeloma.
Journal: Blood cancer journal
Published: July 02, 2025

Frequently Asked Questions about Martin Hoffmann

Is Martin Hoffmann a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Martin Hoffmann is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Martin Hoffmann participate in research or clinical trials?

Yes. Martin Hoffmann has published 15 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Martin Hoffmann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hoffmann's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile